A meta-analysis with trial sequential analysis found evidence favoring remimazolam over propofol for hypotension in elderly general-anesthesia patients. Its information-size conclusion was endpoint-specific; it should not be extended to every recovery or safety outcome.
What the review included
Eleven randomized trials involving 947 patients aged at least 60 years were pooled. The reported risk ratio for hypotension was 0.41, with a 95% confidence interval of 0.27 to 0.62. Bradycardia and injection pain also favored remimazolam, while time to loss of consciousness was longer. Emergence time, extubation time, and emergence-agitation incidence did not show clear differences.
What sequential analysis adds
Repeated evidence accumulation can create misleading significance if the amount of information is insufficient. The authors used trial sequential analysis and reported that the required information size was achieved for hypotension. That strengthens that particular statistical assessment under its assumptions. It does not guarantee an adequate sample for rare harms, subtle cognitive effects, or every secondary endpoint.
Why anesthesia protocols remain important
The trials varied in dose, surgical procedure, and use of flumazenil; four trials used the antagonist. The authors considered recovery subgroups and noted that limited comparable studies restricted more detailed analyses. A report should therefore identify the endpoint supported by the sequential analysis and retain the protocol differences when applying the review to an individual anesthetic course.
Source and scope
This original analysis uses the supplied paper: Remimazolam vs propofol for general anaesthesia in elderly patients a meta analysis with trial seque. The interpretation above separates the authors’ findings from their implications for evidence review.
Explore related material through this site’s benzodiazepine articles and remimazolam research discussions.
Leave a Reply